​

Polyrizon Stock (NASDAQ:PLRZ)

FinancialsChart
Polyrizon by TradingView

Previous Close

$12.40

52W Range

$2.88 - $7.20K

50D Avg

$6.48

200D Avg

$212.03

Market Cap

$12.74M

Avg Vol (3M)

$3.09M

Beta

-4.50

Div Yield

-

PLRZ Company Profile

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IL

Employees

2

IPO Date

Oct 29, 2024

Website

PLRZ Performance

PLRZ Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-1.30M$-635.00K$-895.00K
Net Income$-1.54M$-600.00K$-779.00K
EBITDA$-1.18M$-594.00K$-772.00K
Basic EPS-$-0.16$-0.20
Diluted EPS-$-0.16$-0.20

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
RADXRadiopharm Theranostics Limited
XTLBXTL Biopharmaceuticals Ltd.
PMCBPharmaCyte Biotech, Inc.
VYNEVYNE Therapeutics Inc.
QNRXQuoin Pharmaceuticals, Ltd.
KTTAPasithea Therapeutics Corp.
TCRTAlaunos Therapeutics, Inc.
CYCNCyclerion Therapeutics, Inc.